Clinical trials: Carcinoma Breast
Gynecologic Cancer, Gynecologic Neoplasms
Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis
Background: Tumors that have spread to the lining of the abdomen from other cancers, such as cancer of the appendix, colon, or ovary, are called peritoneal carcinomatosis. In most cases, outcomes are poor.
- Conditions
- Gynecologic Cancer, Gynecologic Neoplasms, Peritoneal Carcinomatosis, Peritoneal Neoplasms
- Trial name
- NCT05185947
- Testing
- Paclitaxel, Nilotinib, ECG
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Breast Mass, Breast Cancer
Predicting Breast Cancer With the BRAVE System
Breast cancer predominates among cancer diagnoses in Canadian women. It accounts for around 25% of new cases and contributes to 13% of all cancer-related deaths.
- Trial name
- BRAVE (NCT06498388)
- Testing
- Stiffness measurement by visco-elastography
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- Université de Sherbrooke
Breast Cancer
Psychosocial Adjustment of Patients and Their Partners Following Breast Cancer Diagnosis
The purpose of this study is to describe psychosocial adjustment in patients with breast cancer and their cohabiting partners/spouses throughout the cancer trajectory, to study mutual influences of the partner on the patient and…
- Trial name
- NCT01392066
- Testing
- questionnaire
- Where
- Denmark
- Volunteers
- 1,584 people
- Sponsor
- University of Southern Denmark
Breast Cancer
High Five (HiFi) Accelerated Partial Breast Irradiation Study
To establish the role of adjuvant multicatheter interstitial high-dose-rate brachytherapy in doubly accelerated and radiobiologically equivalent irradiation scheme of 5 x 5,4 Gy in 3 days of treatment (High Five, HiFi-APBI)…
- Trial name
- HiFi (NCT05142202)
- Testing
- Breast Irradiation after Breast-Conserving Surgery
- Where
- Poland
- Volunteers
- 147 people
- Sponsor
- The Greater Poland Cancer Centre
Breast Cancer
A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)
The goal of this clinical research study is to find the best dose of the drugs cyclophosphamide and axatilimab that can be given in combination with the standard dose of retifanlimab to patients with metastatic TNBC.
- Trial name
- NCT06959537
- Testing
- Cyclophosphamide, Axatilimab (SNDX-6352), Retifanlimab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer Female
Cognitive Rehabilitation Following Breast Cancer Treatment
The goal of this proposed project is to evaluate the feasibility and preliminary effect of metacognitive strategy training to improve activity performance, cognition, and quality of life in breast cancer survivors with…
- Trial name
- NCT06545045
- Testing
- Metacognitive Strategy Training (MCST), Inactive Control Group
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Missouri-Columbia
Breast Cancer
Nurse Navigation Program Based On Health Belief Model In Breast Cancer Screening (NaHeB-CaS)
This study, which is designed according to the experimental model with randomized pre-test and post-test control group, will be carried out with Syrian women who apply to Empowered Migrant Health Center in İstanbul province…
- Trial name
- NaHeB-CaS (NCT04966377)
- Testing
- Nurse Navigation Program Based On Health Belief Model In Breast Cancer Screening (NaHeB-CaS)
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Ondokuz Mayıs University
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
This phase II MATCH treatment trial identifies the effects of GDC-0032 (taselisib) in patients whose cancer has a genetic change called PIK3CA mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439175
- Testing
- Taselisib
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Renal Cell Carcinoma
Everolimus TDM to Predict Long Term Toxicity
Metastatic (HR-positive, HER2-negative) breast cancer (BC), advanced or unresectable neuroendocrine tumours of pancreatic (pNET), gastrointestinal or lung origin and metastatic renal cell carcinoma (mRCC) are diseases with poor…
- Conditions
- Breast Cancer, Renal Cell Carcinoma, Pancreatic Neuroendocrine Tumour, Gastrointestinal Neuroendocrine Tumour
- Trial name
- Foresight (NCT03033186)
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Maastricht University Medical Center
Locally Advanced or Metastatic Breast Cancer
A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain
The purpose of this study is to evaluate the effectiveness and safety of capivasertib + fulvestrant treatment administration in patients with locally advanced (inoperable) or metastatic HR+ / HER2- breast cancer with…
- Trial name
- CAPItana (NCT06764186)
- Testing
- Fulvestrant, Capivasertib
- Where
- 17 sites in Spain
- Volunteers
- 101 people
- Sponsor
- AstraZeneca
Invasive Ductal Carcinoma, Ductal Carcinoma in Situ
Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®
The purpose of this trial is to assess the safety and efficacy of the Xoft Axxent eBx System when used for single-fraction IORT in early stage breast cancer.
- Trial name
- NCT01644669
- Testing
- Intra-operative Radiation Therapy - IORT
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 1,200 people
- Sponsor
- Xoft, Inc.
Breast Cancer
Evaluation of a 3D Functional Metabolic Imaging and Risk Assessment System in Classifying Women for Likelihood of Breast Cancer
The study objective is to evaluate the added value of MIRA technology as an adjunct to mammography in the detection of malignant breast lesions in women with dense breast and/or at elevated risk of breast cancer.
- Trial name
- NCT03296683
- Testing
- MIRA device imaging
- Where
- Italy
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Real Imaging Ltd.
Metastatic Breast Cancer
Improving the Approach to and Management of the Older Metastatic Breast Cancer Patient
The purpose of this study is to enhance the care of older metastatic breast cancer (MBC) patients by increasing awareness among oncology providers as to the unique aspects of care required for older patients.
- Trial name
- NCT03007641
- Testing
- Didactic session, Comprehensive Geriatric Assessment
- Where
- 5 sites in United States
- Volunteers
- 100 people
- Sponsor
- Fox Chase Cancer Center
Metastatic Breast Cancer
Multi-peptide Vaccine With Basilixumab for Breast Cancer
Eligible patients will receive subcutaneous vaccinations of the hTERT/survivin/CMV multipeptide vaccine and GM-CSF over a 24 month period. All patients will receive basiliximab 20 mg 1 day prior to the start of vaccinations.
- Trial name
- NCT01660529
- Testing
- hTERT
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer Female
PreOperative Endocrine Therapy for Individualised Care With Abemaciclib
POETIC-A is a phase 3 trial which targets post-menopausal primary breast cancer patients with a high 5-year risk of relapse as determined by a high Ki67 after 2 weeks aromatase inhibitor therapy pre-surgery.
- Trial name
- POETIC-A (NCT04584853)
- Testing
- Abemaciclib, Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)
- Where
- 62 sites in United Kingdom
- Volunteers
- 123 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Breast Cancer, Neoadjuvant Therapy
Validation of the CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems After PST of BC in China
Prognostic assessment after preoperative systemic therapy (PST) plays a vital role in breast cancer patients. The clinical-pathologic staging system incorporating estrogen receptor (ER)-negative disease and nuclear grade 3 tumor…
- Conditions
- Breast Cancer, Neoadjuvant Therapy, Neoplasm Staging, Estrogen Receptor
- Trial name
- NCT03437837
- Where
- 12 sites in China
- Volunteers
- 1,077 people
- Sponsor
- Peking University First Hospital
Breast Cancer, Estrogen Receptor Positive Tumor
Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure
This is an open-label, multicentric, international, phase II trial testing aromatase inhibitors in combination with durvalumab in patients with CD8+ T cell infiltration (>10% CD8+ T cells in the tumor).
- Conditions
- Breast Cancer, Estrogen Receptor Positive Tumor, Menopause, Hormone Antagonist
- Trial name
- ULTIMATE (NCT02997995)
- Testing
- Immune-attractant, Durvalumab, Biopsy
- Where
- 29 sites in France, Spain and 1 more
- Volunteers
- 61 people
- Sponsor
- UNICANCER
Fatigue
Intravenous Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer
This is a parallel-track, randomized study will observe whether intravenous ascorbic acid reduces the reported fatigue in women receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer.
- Trial name
- NCT02521077
- Testing
- Ascorbic Acid, Normal Saline
- Sponsor
- Midwestern Regional Medical Center
Skin Sympathetic Nerve Activity During General Anesthesia in Patients Undergoing Breast Cancer Surgery
Measurement of the Skin Sympathetic Nerve Activity
Sympathetic nerve activity can be measured transcutaneously in awake patients by computer-based filtering of raw signal obtained via skin leads attached on the chest.
- Trial name
- NCT03658057
- Testing
- Rocuronium
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Seoul National University Hospital
Breast Cancer
10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)
10-year CHD risk evaluation and its treatment pattern analysis in postmenopausal early breast cancer patients taking aromatase inhibitors.
- Trial name
- NCT00885612
- Where
- 27 sites in South Korea
- Volunteers
- 1,114 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.